[26PS1-am] Pharmacotherapies (Cancer) 1

Sun. Mar 26, 2023 9:00 AM - 10:00 AM [Room PS1] (1F)

Chair: Ryuji Ikeda, Mina Nitta

+Add all to schedule

9:00 AM - 9:12 AM

[26PS1-am01S] Role of Moesin in regulating the cell surface localization of PD-L1 in human uterine cervical squamous cell carcinoma

○Rina Doukuni¹, Takuro Kobori¹, Chihiro Tanaka¹, Mayuka Tameishi¹, Yoko Urashima¹, Takuya Ito¹, Tokio Obata¹ (1. Facult. Pharm., Osaka Ohtani Univ.)

9:12 AM - 9:24 AM

[26PS1-am02S] Involvement of Ezrin/Radixin/Moesin in the cell surface expression of immune checkpoint molecule PD-L1 in human endometrial carcinoma cell line

○Yui Ito¹, Takuro Kobori¹, Chihiro Tanaka¹, Yoko Urashima¹, Takuya Ito¹, Nobumasa Takagaki², Tokio Obata¹ (1. Osaka Ohtani Univ., 2. Nobumasa Clinic)

9:24 AM - 9:36 AM

[26PS1-am03] Development of a immune checkpoint inhibitor-related myocarditis model mouse using genome-edited mice

○takahiro niimura^1,2, Hiroto Unten², Hirofumi Hamano^1,3, Kazushi Uchida², Tomochika Nanami², Koji Miyata², Mitsuhiro Goda^2,4, Kenta Yagi^1,2, Fuka Aizawa^4,2, Yuki Izawa-Ishizawa², Yoshito Zamami^2,3, Keisuke Ishizawa^1,2,4 (1. Clin. Res. Ctr. Dev. Therap, Tokushima Univ. Hosp., 2. Grad. Sch. Biomed. Sci., Tokushima Univ., 3. Dept. Pharm., Okayama Univ. Hosp., 4. Dept. Pharm., Tokushima Univ. Hosp.)

9:36 AM - 9:48 AM

[26PS1-am04] A retrospective cohort study of clinical outcomes and immune-related adverse events among patients with cancer receiving immune checkpoint inhibitors

○Hiroki Hata^1,2, Chikako Matsumura¹, Yugo Chisaki¹, Nishioka Kae¹, Misaki Tokuda¹, Kazuyo Miyagi², Tomoki Suizu², Yoshitaka Yano¹ (1. Kyoto Pharmaceutical University, 2. Department of Pharmacy, National Hospital Organization Osaka National Hospital)

9:48 AM - 10:00 AM

[26PS1-am05] Fact-finding survey on renal injury during administration of immune checkpoint inhibitors

○Kazuya Uenoyama¹, Masahide Onoue¹ (1. Department of Pharmacy, Kitano Hospital Tazuke Kofukai Medical Research Institute)

Session information